#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16038	16S	1529	1529	99.93	16S.l15.c17.ctg.2	2242	850.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1693	1693	T	1072	T,G,C,A	1064,4,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16038	16S	1529	1529	99.93	16S.l15.c17.ctg.2	2242	850.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1427	1427	C	985	C,T	984,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26900	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4197	800.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1954	1954	A	1044	A,T,G	1042,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26900	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4197	800.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2588	2588	C	1033	C	1033	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26900	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4197	800.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2662	2662	A	942	A,G,C	939,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26900	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4197	800.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3214	3214	C	936	C,T	934,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2538	folP	855	855	100.0	folP.l6.c4.ctg.1	1951	162.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1244	1246	AGC	241;242;245	A;G;C	241;242;245	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5912	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3931	187.8	1	SNP	p	S91F	1	.	.	271	273	TTC	883	885	TTC	235;235;233	T;T,C;C	235;234,1;233	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5912	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3931	187.8	1	SNP	p	G95N	0	.	.	283	285	GGC	895	897	GGC	239;239;242	G;G;C	239;239;242	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5912	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3931	187.8	1	SNP	p	D95G	1	.	.	283	285	GGC	895	897	GGC	239;239;242	G;G;C	239;239;242	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	2160	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1779	151.6	1	SNP	p	G45D	0	.	.	133	135	GGC	694	696	GGC	270;268;269	G;G,T;C	270;267,1;269	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1152	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1495	96.2	0	.	n	.	0	A197.	DEL	197	197	A	844	844	A	214	A	214	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5360	parC	2304	2304	99.87	parC.l15.c17.ctg.1	3442	194.2	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1736	1738	GTC	239;235;235	G;T;C	239;235;235	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5360	parC	2304	2304	99.87	parC.l15.c17.ctg.1	3442	194.2	1	SNP	p	D86N	0	.	.	256	258	GAC	842	844	GAC	234;234;232	G,A;A;C	233,1;234;232	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5360	parC	2304	2304	99.87	parC.l15.c17.ctg.1	3442	194.2	1	SNP	p	R87I	0	.	.	259	261	CGT	845	847	CGT	230;235;233	C;G;T,G	230;235;232,1	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5360	parC	2304	2304	99.87	parC.l15.c17.ctg.1	3442	194.2	1	SNP	p	R87W	0	.	.	259	261	CGT	845	847	CGT	230;235;233	C;G;T,G	230;235;232,1	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5360	parC	2304	2304	99.87	parC.l15.c17.ctg.1	3442	194.2	1	SNP	p	S87R	1	.	.	259	261	CGT	845	847	CGT	230;235;233	C;G;T,G	230;235;232,1	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5360	parC	2304	2304	99.87	parC.l15.c17.ctg.1	3442	194.2	1	SNP	p	S88P	0	.	.	262	264	TCC	848	850	TCC	237;235;235	T;C;C	237;235;235	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4664	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3240	179.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1617	1619	TGC	258;258;255	T,G,C;G;C	256,1,1;258;255	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4664	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3240	179.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1827	1829	GGC	280;278;276	G;G;C,A	280;278;275,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1546	1548	GCA	247;248;245	G,T;C;A	246,1;248;245	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1549	1551	ATC	244;244;242	A;T,G;CAAA,CAA	244;243,1;233,1	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1561	1563	GTG	235;236;237	G;T;G	235;236;237	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1561	1563	GTG	235;236;237	G;T;G	235;236;237	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2065	2067	ACC	250;253;253	A,C;C;C	249,1;253;253	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2119	2121	GCG	235;235;236	G;C;G	235;235;236	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2119	2121	GCG	235;235;236	G;C;G	235;235;236	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2242	2244	GGC	247;250;252	G;G;C	247;250;252	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2251	2253	GGC	259;259;263	G,C;G,A;C	258,1;258,1;263	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2984	183.5	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2269	2271	TCG	263;265;262	T,C,G;C,A;G	260,2,1;264,1;262	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5866	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3645	200.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1954	1956	CCG	224;223;220	C,G;C,T;G	223,1;221,1;220	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2970	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2449	151.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	881	881	C	203	C	203	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	560	302	porB1a	984	112	91.96	porB1a.l6.c4.ctg.2	839	23.4	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	64;64;61	A;C;G	64;64;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	560	302	porB1a	984	112	91.96	porB1a.l6.c4.ctg.2	839	23.4	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	18;16;12	C;A;A	18;16;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	560	302	porB1a	984	112	91.96	porB1a.l6.c4.ctg.2	839	23.4	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	181	183	TAC	2;2;1	T;A;C	2;2;1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	658	660	GAA	293;293;292	G;A,T;A,C	293;292,1;291,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	946	948	GAT	268;266;266	G;A;T	268;266;266	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1069	1071	TCA	254;255;255	T;C;A	254;255;255	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1198	1200	GTC	286;288;289	G;T;C,T,G	286;288;287,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1528	1530	GCA	214;215;215	G;C;A	214;215;215	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	0	.	p	.	0	D333V	NONSYN	997	999	GAC	1543	1545	GTC	209;207;211	G;T;C	209;207;211	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	1	SNP	p	G120K	1	.	.	358	360	AAG	904	906	AAG	269;271;270	A;A;G	269;271;270	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	1	SNP	p	D121N	0	.	.	361	363	GAC	907	909	GAC	272;274;270	G;A;C	272;273;270	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3176	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2012	196.7	1	SNP	p	A121D	1	.	.	361	363	GAC	907	909	GAC	272;274;270	G;A;C	272;273;270	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10588	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5496	240.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2339	2341	AAT	265;263;265	A;A,T;T	265;262,1;265	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1548	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1519	127.1	1	SNP	p	V57M	1	.	.	169	171	ATG	761	763	ATG	275;275;275	A;T;G	275;275;275	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
